Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Antibody-drug conjugates utilize the targetting potential of antibodies to improve the potential of cytostatic or cytocidal drugs. One such murine monoclonal antibody, CTM01 (mCTM01), which recognizes an epitope on breast epithelial mucin, has potential for the treatment of breast and ovarian cancers. We examine in this paper the comparative properties of mCTM01 against a number of other anti-mucin antibodies. We then describe the humanization and high level re-expression of humanized CTM01 (hCTM01), a process designed to avoid the immune response to administered murine antibodies in human patients and to produce sufficient material for clinical studies. We show that the humanized form has properties superior to mCTM01 in terms of binding affinity to antigen presented on tumour cells.


Journal article


Adv Exp Med Biol

Publication Date





61 - 82


Amino Acid Sequence, Animals, Antibodies, Monoclonal, Antibody Affinity, Antigens, Neoplasm, Breast Neoplasms, Enzyme-Linked Immunosorbent Assay, Female, Humans, Immunotherapy, Membrane Glycoproteins, Mice, Minisatellite Repeats, Molecular Sequence Data, Mucin-1, Mucins, Neoplasm Proteins, Ovarian Neoplasms, Peptide Fragments, Protein Engineering, Recombinant Fusion Proteins